Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.BACKGROUND
 Decisions on palliative chemotherapy (CT) for locally advanced or metastatic gastric cancer (mGC) require trade-offs between potential benefits and risks for patients.  Healthcare providers and payers agree that patient-preferences should be considered.  We conducted a choice-based conjoint (CBC) analysis study in pre-treated patients from Germany with mGC or locally advanced or metastatic adenocarcinoma of the gastroesophageal junction (mGEJ-Ca), to evaluate their preferences when hypothetically selecting a CT regimen.


 German oncologists and gastroenterologists were contacted to identify patients with mGC or mGEJ-Ca who had completed ≥2 cycles of palliative CT in first or later lines of therapy (CT ongoing or complete).  The primary objective was to quantify patient preferences for palliative CT by CBC analysis.  Six in-depth qualitative interviews identified 3 attributes: treatment tolerability, quality of life in terms of ability of self-care, and additional survival benefit.  The CBC matrix was constructed with 4 factor levels per attribute and each participant was presented with 15 different iterations of these levels.  A minimum of 50 participants was needed.  Consenting patients completed the CBC survey, choosing systematically among profiles.  CBC models were estimated by multinomial logistic regression (MLR) and hierarchical Bayesian (HB) analysis.  Estimates of importance for each attribute and factor-level were calculated.


 Fifty-five patients participated in the CBC survey (78.2% male, median age 63 years, 81.8% currently receiving CT).  Across this sample, low treatment toxicity was ranked highest (44.6% relative importance, MLR analysis), followed by ability to self-care (32.3%), and an additional survival benefit of up to 3 months (3 months 23.1%, 2 months 18.3%, 1 month 11.2%).  The MLR analysis showed high validity (certainty 37.9%, chi square p < 0.01, root-likelihood 0.505).  CONCLUSIONS
 Patients' preferences related to a new hypothetical palliative CT of mGC or mGEJ-Ca can be assessed by CBCanalysis.  Although in real-life, patients initially need to decide on CT before they have any experience, and patients' varied experiences with CT will have impacted specific responses, low toxicity and self-care ability were considered as most important by this group of patients with mGC or mGEJ-Ca.
C